It recorded a net loss of $39.7 million. Diluted earnings per share were -$3.38. Across the 4 fiscal years shown, revenue shrank from $90,000 in fiscal 2019 to $90,000 in fiscal 2022, about 0.0% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
FY 2020
Sep 30, 2020
|
FY 2019
Sep 30, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
|
—
|
0
+0.0%
|
0
+0.0%
|
0
+0.0%
|
0
|
| Research and development |
6
-43.2%
|
9
-23.1%
|
12
-19.7%
|
15
-16.1%
|
18
+44.2%
|
12
+38.9%
|
9
+2.5%
|
9
+31.0%
|
| Selling, general and administrative |
42
+109.6%
|
19
+1.6%
|
18
+19.3%
|
15
+30.1%
|
12
+19.5%
|
10
+21.5%
|
8
+28.8%
|
6
-2.5%
|
| Operating income |
-61
-49.2%
|
-39
+8.3%
|
-42
-14.3%
|
-37
-10.3%
|
-33
-41.6%
|
-24
-32.9%
|
-18
-13.5%
|
-16
-13.1%
|
| Interest income |
0
+54.5%
|
0
-85.5%
|
1
-35.7%
|
1
+369.1%
|
0
-4.0%
|
0
+284.7%
|
0
+29.3%
|
0
+6433.5%
|
| Interest expense |
1
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
| Pretax income |
-58
-40.9%
|
-39
+0.4%
|
-39
-21.5%
|
-32
+3.3%
|
-33
|
—
|
-18
-12.8%
|
-16
-224.1%
|
| Income tax |
0
-79.7%
|
1
+83.5%
|
1
+0.0%
|
1
+0.0%
|
1
+46615.3%
|
0
|
—
|
—
|
| Net income |
-58
-38.2%
|
-40
-0.8%
|
-39
-21.2%
|
-33
+3.3%
|
-34
-45.9%
|
-23
-31.4%
|
-18
-12.8%
|
-16
|
| Net income to common |
-46
-12.9%
|
-37
+6.8%
|
-40
-19.3%
|
-34
-0.2%
|
-34
-37.3%
|
-25
|
—
|
—
|
| Basic EPS |
-2.13
+55.6%
|
-3.38
+43.4%
|
-5.97
|
—
|
-0.23
|
—
|
—
|
—
|
| Diluted EPS |
-2.13
+55.6%
|
-3.38
+43.4%
|
-5.97
|
—
|
-0.23
|
—
|
—
|
—
|
| Weighted average shares, basic |
22
+154.1%
|
11
+64.5%
|
7
+11.2%
|
6
-95.9%
|
146
|
—
|
—
|
—
|
| Weighted average shares, diluted |
22
+154.1%
|
11
+64.5%
|
7
+11.2%
|
6
-95.9%
|
146
|
—
|
—
|
—
|
| Other measures | ||||||||
| Depreciation and amortization |
—
|
0
|
—
|
0
-8.7%
|
0
+95.9%
|
0
+76.8%
|
0
-5.5%
|
0
-49.1%
|
| EBITDA |
—
|
-39
|
—
|
-37
-10.3%
|
-33
-41.6%
|
-24
-32.9%
|
-18
-13.5%
|
-16
-13.1%
|
| Interest coverage |
-119.00x
|
-143.87x
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | ||||||||
| Operating margin |
—
|
—
|
—
|
—
|
-37,017.83%
|
-26,146.55%
|
-19,678.54%
|
-17,331.51%
|
| Pretax margin |
—
|
—
|
—
|
—
|
-36,738.50%
|
—
|
-19,497.87%
|
-17,291.27%
|
| Profit margin |
—
|
—
|
—
|
—
|
-37,378.50%
|
-25,616.04%
|
-19,497.87%
|
-17,291.27%
|
| EBITDA margin |
—
|
—
|
—
|
—
|
-37,014.58%
|
-26,144.89%
|
-19,677.60%
|
-17,330.52%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTXR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- Cranford, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1506251
- Former names
- Trail One, Inc. (until Sep 18, 2014); TrailOne, Inc. (until Jan 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.